Cor Vasa 2004, 45(9):447-449

VALUE for blood pressure. VALUE trial results have documented the key role of a blood pressure decrease

Jindřich Špinar^1,*, Jiří Vítovec²

¹ Interní-kardiologická klinika, Fakultní nemocnice Brno

² I. interní-kardioangiologická klinika, Fakultní nemocnice u sv. Anny a Lékařská fakulta Masarykovy univerzity, Brno, Česká republika

The VALUE trial was designed to compare valsartan (at a dose of 160 mg) with amlodipine (at a dose of 10 mg) in hypertensive patients at increased risk for cardiovascular complications. The study demonstrated more effective blood pressure control associated with amlodipine, as also reflected by the lower incidences of myocardial infarction (p = 0.02) and stroke (p = 0.08). Valsartan-treated patients showed a lower incidence of new-onset diabetes mellitus (p < 0.001). After adjustment to comparable blood pressure values, the incidence of cardiovascular complications was identical in both groups. Thus, the VALUE trial confirmed both the main outcome of the ALLHAT study and the essential role played by a decrease in blood pressure in the treatment of hypertension.

Keywords: VALUE; Valsartan; Amlodipine; Hypertension; Diabetes mellitus

Published: September 1, 2004  Show citation